Advertisement

  

International News

Gilead Lowers Its No-Profit Drug Prices

From U.S. Centers for Disease Control and Prevention

August 30, 2005


This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

On Monday, Gilead Sciences Inc. announced it is reducing the prices it charges developing nations for its HIV drugs Truvada and Viread. Through its access program, Gilead sells the drugs at no profit to a group of 97 developing countries. The lower prices are possible, Gilead said, thanks to increased economies of scale, a new factory in the Bahamas and manufacturing improvements that have lowered costs. The move cuts the countries' costs for Viread by 31 percent to $17 per patient per month and for Truvada by 12 percent to $26.25 per patient per month. Viread's inventors have waived their royalty rights on sales to the participating countries; Viread is contained in the combination treatment Truvada.

Back to other news for August 30, 2005

Adapted from:
Associated Press
08.29.05




  
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 

Advertisement
Advertisement